首页> 外文OA文献 >312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)

【2h】

312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)

机译：312 ARIES：阶段，开放标签研究，以评估Rucaparib（PARP抑制剂）与卵巢或尿路上皮癌（UC）的患者中的Nivolumab（抗PD-1抗体）组合

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
K Moore; K Redhead; S Goble; O Bowles; KK Lin; A Tripathi;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors [J] . Kristeleit Rebecca, Shapiro Geoffrey I., Burris Howard A., Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第15期

机译：患有种系BRCA1 / 2型突变卵巢癌或其他实体瘤患者口腔PARP抑制剂Rucaparib的I-II期研究
2. Evaluation of rucaparib and companionydiagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy [J] . Jenner Zachary B., Sood Anil K., Coleman Robert L. Future oncology . 2016,第12期

机译：在复发性卵巢癌治疗中PARP抑制剂领域的rucaparib和伴随诊断的评估
3. Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer [J] . Lin K., Tinker A. V., Kondrashova O., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：RAD51C和RAD51D的继发突变与高级别卵巢癌患者对PARP抑制剂rucaparib的获得性耐药有关
4. Apply Radiomics Approach for Early Stage Prognostic Evaluation of Ovarian Cancer Patients: A Preliminary Study [C] . Gopichandh Danala, Yunzhi Wang, Theresa Thai, Conference on Computer-Aided Diagnosis . 2017

机译：应用放射性组学方法对卵巢癌患者进行早期预后评估：初步研究
5. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study [D] . Kobayashi Tomoko, 小林朋子 2019

机译：抗甲状腺抗体的患者通过Nivolumab容易发展为破坏性甲状腺炎：一项前瞻性研究
6. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy [O] . Zachary B Jenner, Anil K Sood, Robert L Coleman -1

机译：在复发性卵巢癌治疗中PARP抑制剂领域中rucaparib和伴随诊断的评估
7. Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile [O] . Domenica Lorusso, Giuseppa Maltese, Ilaria Sabatucci, 2020

机译：I阶段研究Rucaparib与卵巢癌患者的Bevacizumab组合：最大耐受剂量和药代动力学曲线

312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)

著录项

引文网络

相似文献

相关主题

期刊订阅